Use of Drugs With Actionable Pharmacogenetic Biomarkers and Possible Prescribing Changes Among Older People.

ABSTRACT:

Background

Pharmacogenetic testing offers a pathway to safer prescribing and improved outcomes in older adults, who face heightened risks of adverse drug reactions due to polypharmacy and age-related metabolic changes. This study evaluates the prevalence of actionable pharmacogenetic biomarker use and estimates the potential impact of genotype-guided dosing in Chinese older adults.

Methods

This retrospective cross-sectional analysis utilized 2015-2017 claims data from the China Health Insurance Research Association (CHIRA), encompassing 3,309,025 older patients (≥ 65 years) and 74,415,484 prescriptions. Drugs with Clinical Pharmacogenomics Implementation Consortium (CPIC) Level A evidence for actionable pharmacogenetic variants (n = 53) were identified. Key measures included

SUBMITTER: Zhao Z 

PROVIDER: S-EPMC12748018 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature